CI

At a glance

ClinicalIndex Comparison Record
Phase 3Active· 445 enrolled
Drug / intervention
AK104 +5 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04982237
NCT04982237Phase 3Active
CompareCT.gov

A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate AK104 Plus Platinum-containing Chemotherapy With or Without Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

Akeso·interventional·Posted Jul 29, 2021·Updated Nov 19, 2025

In Brief

A Phase 3 clinical trial evaluating AK104, paclitaxel, and 4 other interventions for Cervical Cancer. Active but no longer recruiting, targeting 445 participants across 5 sites.

Detailed Summary

This is A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate AK104 Plus Platinum-containing Chemotherapy With or Without Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCervical Cancer
CountriesChina
Collaborators--

Timeline

Phase 3ActiveOverdue
20222023202420252026
First PostedJul 29, 2021
Enrollment StartAug 27, 2021
Primary CompletionDec 30, 2025
TodayJul 1, 2026
Enrollment to primary: 4.3 yearsPosted 4.9 years ago

Interventions

AK104biological

IV infusion

paclitaxeldrug

IV infusion

carboplatindrug

iv infusion

cisplatindrug

iv infusion

bevacizumabdrug

iv infusion

Placebodrug

iv infusion